FDA Warns Momentum Health Over Compounded Semaglutide, Tirzepatide, and Liraglutide Marketing
On June 8, 2026, FDA issued a warning letter to Momentum Health 360 dba Momentum Health after a March 2026 review of momentumhealth360.com, which offers compounded semaglutide, tirzepatide, and liraglutide products. FDA says pictured labels identify "Momentum Health" as if it were the compounder "when in fact it is not," and cites claims including "Same active ingredient in Mounjaro® and Zepbound™" and an "FDA-licensed compounding facility" reference FDA calls "false and misleading." FDA requested a written response within 15 business days.
What this meansFDA does not approve or license compounding pharmacies, so "FDA-approved pharmacy" language on a provider's site is worth questioning — how a provider describes its pharmacy partners says a lot about how carefully it operates.
Source: FDA original ↗